Yanhu Dong Selected Research

fluchloralin

1/2019	A Propensity Score Matched Comparison of Brand and Biosimilar Basal Insulin in Non-Critical Hospitalized Patients with Type 2 Diabetes Mellitus.
1/2018	Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yanhu Dong Research Topics

Disease

2	Hypoglycemia (Reactive Hypoglycemia) 01/2019 - 01/2018
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2010 - 04/2007
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Diabetes Mellitus 01/2018
1	Prediabetic State (Prediabetes) 04/2010
1	Dyslipidemias (Dyslipidemia) 04/2010
1	Hyperuricemia 03/2008
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2008
1	Glucose Intolerance 01/2008
1	Coronary Disease (Coronary Heart Disease) 04/2007
1	Hypertension (High Blood Pressure) 04/2007

Drug/Important Bio-Agent (IBA)

2	Biosimilar PharmaceuticalsIBA 01/2019 - 01/2018
2	Insulin Glargine (Lantus)FDA Link 01/2019 - 01/2018
2	Blood Glucose (Blood Sugar)IBA 01/2019 - 01/2018
2	Insulin (Novolin)FDA Link 01/2019 - 01/2018
2	fluchloralinIBA 01/2019 - 01/2018
2	Glucose (Dextrose)FDA LinkGeneric 04/2010 - 01/2008
2	Triglycerides (Triacylglycerol)IBA 03/2008 - 04/2007
2	Uric Acid (Urate)IBA 03/2008 - 04/2007
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019
1	LipidsIBA 04/2010
1	HDL CholesterolIBA 04/2010